Global Blood Therapeutics, Inc. (NASDAQ:GBT) Receives $88.38 Consensus PT from Brokerages


Share on StockTwits

Global Blood Therapeutics, Inc. (NASDAQ:GBT) has earned an average recommendation of “Buy” from the twenty analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $85.82.

A number of equities analysts have recently commented on GBT shares. Morgan Stanley cut their price objective on shares of Global Blood Therapeutics from $67.00 to $45.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 16th. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating and set a $45.00 price objective for the company in a research report on Tuesday. Wolfe Research started coverage on shares of Global Blood Therapeutics in a research report on Wednesday, March 17th. They issued an “outperform” rating and a $67.00 price objective for the company. William Blair lowered shares of Global Blood Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Global Blood Therapeutics in a research report on Tuesday, December 15th.

Several hedge funds have recently bought and sold shares of GBT. Aperio Group LLC increased its stake in shares of Global Blood Therapeutics by 15.2% in the third quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock worth $418,000 after buying an additional 999 shares during the period. SG Americas Securities LLC increased its stake in shares of Global Blood Therapeutics by 136.0% in the third quarter. SG Americas Securities LLC now owns 6,287 shares of the company’s stock worth $347,000 after buying an additional 3,623 shares during the period. Neuberger Berman Group LLC increased its stake in shares of Global Blood Therapeutics by 0.9% in the third quarter. Neuberger Berman Group LLC now owns 236,158 shares of the company’s stock worth $13,013,000 after buying an additional 2,000 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Global Blood Therapeutics by 2.7% in the third quarter. UBS Asset Management Americas Inc. now owns 74,219 shares of the company’s stock worth $4,092,000 after buying an additional 1,958 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Global Blood Therapeutics by 0.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 310,646 shares of the company’s stock worth $17,130,000 after buying an additional 957 shares during the period.

Shares of GBT stock traded down $1.06 during trading hours on Thursday, reaching $41.22. The stock had a trading volume of 961,885 shares, compared to its average volume of 996,965. The stock’s fifty day simple moving average is $43.44 and its 200 day simple moving average is $47.77. The company has a current ratio of 7.63, a quick ratio of 7.20 and a debt-to-equity ratio of 0.16. Global Blood Therapeutics has a 12 month low of $36.49 and a 12 month high of $83.69. The firm has a market capitalization of $2.56 billion, a PE ratio of -9.12 and a beta of 1.39.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Tuesday, February 23rd. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.03). Global Blood Therapeutics had a negative net margin of 332.94% and a negative return on equity of 56.43%. As a group, equities research analysts anticipate that Global Blood Therapeutics will post -3.98 EPS for the current fiscal year.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.

Featured Article: What is systematic risk?

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.